Curie Therapeutics Inc.
2F Gill Street
Woburn MA 01801
For Media:
sarah@argotpartners.com
For Investors:
kevin@argotpartners.com
News & Media
The latest on Curie Therapeutics
Curie Therapeutics Recognized as a 2022 Prix Galien USA Nominee for Prix Galien Startup
CAMBRIDGE, Mass., August 17, 2022 – Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Curie a 2022 Prix Galien USA Award nominee for “Prix Galien Startup.” Winners will be…
03/14/22
Curie Therapeutics Appoints Georgette Verdin as Chief People Officer
03/08/22
Curie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director
02/07/22
Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer
02/03/22
Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors
12/01/21
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals